This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Use of Erythromycin in Mustard-Induced Bronchiolitis

This study has been completed.
Sponsor:
Information provided by:
Baqiyatallah Medical Sciences University
ClinicalTrials.gov Identifier:
NCT00367419
First received: August 21, 2006
Last updated: November 4, 2008
Last verified: March 2006
  Purpose
We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans

Condition Intervention Phase
Bronchiolitis Obliterans Acute Obliterating Bronchiolitis Drug: Erythromycin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans

Resource links provided by NLM:


Further study details as provided by Baqiyatallah Medical Sciences University:

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Criteria

Inclusion Criteria:

  • Documented chemical exposure
  • Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)
  • Non-responsiveness to high dose bronchodilator therapy

Exclusion Criteria:

  • Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic
  • History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides
  • History of treatment with a systemic antibiotic within 7 days before the start of the study
  • Any investigational medicine within 4 weeks of the study
  • History of antibiotic injection within 6 weeks before the study
  • Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored
  • Patients who were in the exacerbation phase of their respiratory complications
  • Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine
  • Systemic antibiotics
  • Systemic Corticosteroids
  • Admission to the hospital
  • Abnormal kidney or liver function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00367419

Locations
Iran, Islamic Republic of
Baqiyatallah Medical Sciences University
Tehran, Iran, Islamic Republic of, 19945-546
Sponsors and Collaborators
Baqiyatallah Medical Sciences University
Investigators
Study Director: Mostafa Ghanei, Professor Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran
  More Information

ClinicalTrials.gov Identifier: NCT00367419     History of Changes
Other Study ID Numbers: S-340-14-6-1-PU-02
Study First Received: August 21, 2006
Last Updated: November 4, 2008

Additional relevant MeSH terms:
Bronchiolitis
Bronchiolitis Obliterans
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Anti-Bacterial Agents
Anti-Infective Agents
Gastrointestinal Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 23, 2017